Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia
NCT ID: NCT01232855
Last Updated: 2015-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2010-11-30
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute promyelocytic leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01232842
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
NCT01035307
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01295476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Demonstrate that S100A10 is expressed on APL cells and that levels of S100A10 correspond to the amount of fibrinolytic activity.
* Evaluate the impact of ATRA on S100A10 level and fibrinolytic activity in vitro.
* Evaluate the impact of S100A10 knockdown on fibrinolytic activity.
* Correlate in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy.
OUTLINE: This is a multicenter study.
Previously collected samples are analyzed via flow cytometry and western blot analysis. Cell surface levels of S100A10 and annexin A2 are correlated to the promyelocyte population and total protein levels are examined to determine total annexin A2 and S100A10 in acute promyelocytic leukemia cells.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
protein expression analysis
western blotting
flow cytometry
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute promyelocytic leukemia
* Available cryopreserved cells from diagnosis or cryopreserved cells from remission (germline)
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason N. Berman, MD
Role: PRINCIPAL_INVESTIGATOR
IWK Health Centre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML11B5
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02844
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML11B5
Identifier Type: OTHER
Identifier Source: secondary_id
AAML11B5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.